Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 1,101–1,200 of 4,108
Pietrzyk, B., Wyskida, K., Ficek, J., et al. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-2050-3 · Cited by 23
The role of parathyroid hormone (PTH) and vitamin D in falls and hip fracture type
Dretakis, K., & Igoumenou, V. G. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01132-7 · Cited by 25
Zeng, L., Pan, B.-Q., Liang, G.-H., Luo, M., Cao, Y., Guo, D., Chen, H., Pan, J., Huang, H., Liu, Q., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00882 · Cited by 25
Osteoporosis Screening and Treatment: A Collaborative Approach
Goode, S. C., Wright, T. F., & Lynch, C. (2019) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.10.017 · Cited by 27
Jin, Z., Chen, J., Shu, B., Xiao, Y., & Tang, D. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2851-2 · Cited by 23
Lee, T.-H., Song, Y., Kim, H., Sung, Y., & Cho, S. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.4.247 · Cited by 24
Si, L., Winzenberg, T. M., Jiang, Q., & Palmer, A. J. (2015) · Osteoporosis International · doi:10.1007/s00198-014-2999-4 · Cited by 25
Cost and Consequences of Noncompliance to Oral Bisphosphonate Treatment
Eisenberg, D. F., Placzek, H., Gu, T., Krishna, A., & Tulsi, B. B. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.1.56 · Cited by 26
Osteoporosis in the at-risk asthmatic
Aljubran, S. A., Whelan, G. J., Glaum, M. C., & Lockey, R. F. (2014) · Allergy · doi:10.1111/all.12438 · Cited by 23
Loures, M. A. A. D. R., Zerbini, C. A. F., Danowski, J. S., Pereira, R. M. R., Moreira, C., de Paula, A. P., Castro, C. H. D. M., Szejnfeld, V. L., de Mendonça, L. M. C., Radominiski, S. C., et al. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.07.003 · Cited by 29
Chen, X., Zhang, J., & Zhou, Z. (2020) · Obesity Surgery · doi:10.1007/s11695-020-05095-x · Cited by 21
Hayden, A. C., Cotter, E. J., Hennick, T. M., et al. (2023) · JSES International · doi:10.1016/j.jseint.2023.03.012 · Cited by 22
Quantitative Ultrasound and Bone Health in Elderly People, a Systematic Review
Escobio-Prieto, I., Blanco‐Díaz, M., Pinto, E. P., Rodriguez-Rodriguez, A. M., Ruiz-Dorantes, F. J., & Cabello, M. A. (2023) · Biomedicines · doi:10.3390/biomedicines11041175 · Cited by 32
Malabanan, A. O., Rosen, H. N., Vokes, T., Deal, C. L., Alele, J. D., Olenginski, T. P., & Schousboe, J. T. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.08.002 · Cited by 28
Ensrud, K. E., Harrison, S. L., Cauley, J. A., Langsetmo, L., Schousboe, J. T., Kado, D. M., Gourlay, M. L., Lyons, J. G., Fredman, L., Napoli, N., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3020 · Cited by 26
Drug treatment strategies for osteoporosis in stroke patients
Hsieh, C., Sung, S., & Huang, H. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1736556 · Cited by 22
“Clinical practice guidelines for osteoporosis management [13,14] also do not explicitly address stroke in”
BackgroundLi, G., Compston, J. E., Leslie, W. D., Thabane, L., Παπαϊωάννου, Α., Lau, A. N., Wang, X., Qin, C., Chen, B., Chen, M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4139 · Cited by 26
“In this study, we explored the relationship between obesity and risk of major osteoporotic fracture (MOF; ie, a clinical fracture of upper arm or shoulder, hip, spine, or wrist)((15)) in postmenopausal women, after taking frailty into consideration.”
BackgroundMethodYolcu, Y. U., Zreik, J., Alvi, M. A., et al. (2020) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2020.106244 · Cited by 22
Öntan, M. S., Dokuzlar, Ö., Bulut, E. A., Soysal, P., & Işık, A. T. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-021-01213-6 · Cited by 24
“Decreased bone density and bone microarchitecture deterioration, which occur with advancing age, can lead to osteoporosis, a progressive metabolic bone disease associated with increased bone fragility [2].”
BackgroundPapageorgiou, M., & Biver, E. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211009018 · Cited by 23
Current Applications and Selected Technical Details of Dual-Energy X-Ray Absorptiometry
Sawicki, P., Tałałaj, M., Życińska, K., Zgliczyński, W. S., & Wierzba, W. (2021) · Medical Science Monitor · doi:10.12659/msm.930839 · Cited by 33
Patterns of oral bisphosphonate deprescribing in older nursing home residents with dementia
Niznik, J. D., Aspinall, S. L., Hanson, L. C., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06141-9 · Cited by 22
“Osteoporosis-related fractures are costly and can lead to functional dependence, reduced quality of life, and excess mortality [2, 3].”
BackgroundWang, F., Deng, H., Chen, J., et al. (2022) · Bioengineered · doi:10.1080/21655979.2021.2011632 · Cited by 22
“As the most prevalent progressive bone disease, osteoporosis (OP) dramatically limits patient activity and greatly increases the medical burden [1].”
BackgroundSebro, R., & la Garza‐Ramos, C. D. (2022) · Journal of Neuroradiology · doi:10.1016/j.neurad.2022.08.001 · Cited by 23
Wang, Z., Zhai, X., Fang, J., Wu, H., Cheng, Y., Gao, Y., Chen, X., Zheng, S., Liu, S., & Hao, L. (2022) · Nutrients · doi:10.3390/nu14183738 · Cited by 22
Zeitlin, J. H., Parides, M. K., Lane, J. M., Russell, L., & Kunze, K. N. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01292-0 · Cited by 25
“Osteoporosis may not have clinical manifestations prior to the onset of a fragility fracture, which poses challenges for early prevention and diagnosis [1, 2].”
de Melo, T. G., da Assumpção, L. V. M., Santos, A. O., & Zantut‐Wittmann, D. E. (2015) · Thyroid Research · doi:10.1186/s13044-015-0019-1 · Cited by 28
Human Proximal Femur Bone Adaptation to Variations in Hip Geometry
Machado, M. M., Fernandes, P. R., Zymbal, V., & Baptista, F. (2014) · Bone · doi:10.1016/j.bone.2014.07.001 · Cited by 22
Kim, J. W., Jeon, Y.-J., Baek, D., Kim, T. N., & Chang, J. S. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2595-z · Cited by 24
Clinical impact of recent genetic discoveries in osteoporosis
Mitchell, B. D., & Streeten, E. A. (2013) · The Application of Clinical Genetics · doi:10.2147/tacg.s52047 · Cited by 26
Miller‐Martinez, D., Seeman, T. E., Karlamangla, A. S., Greendale, G. A., Binkley, N., & Crandall, C. J. (2014) · Osteoporosis International · doi:10.1007/s00198-013-2602-4 · Cited by 25
Marcucci, G., & Brandi, M. L. (2010) · PubMed · Cited by 22
Evaluating and mitigating fracture risk in established rheumatoid arthritis
Mullen, M. B., & Saag, K. G. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.09.005 · Cited by 27
Exercise for Multimorbid Patients in Primary Care: One Prescription for All?
Barreto, P. D. S. (2017) · Sports Medicine · doi:10.1007/s40279-017-0725-z · Cited by 26
Geriatric Hip Fracture Care: Fixing a Fragmented System
Anderson, M. E., McDevitt, K., Cumbler, E., Bennett, H., Robison, Z., Gomez, B., & Stoneback, J. W. (2017) · The Permanente Journal · doi:10.7812/tpp/16-104 · Cited by 22
Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway
Hoff, M., Skurtveit, S. O., Meyer, H. E., Langhammer, A., Søgaard, A. J., Syversen, U., Skovlund, E., Abrahamsen, B., Forsmo, S., & Schei, B. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4560-3 · Cited by 23
Yang, R., Tao, Y., Wang, C., Shuai, Y., & Jin, L. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.27593 · Cited by 23
Gil-Díaz, M. C., Raynor, J., O'Brien, K. O., Schwartz, G. J., & Weber, D. R. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01334-5 · Cited by 23
Changes in mechanical loading affect arthritis-induced bone loss in mice
Liphardt, A., Windahl, S. H., Sehiç, E., Hannemann, N., Gustafsson, K. L., Bözec, A., Schett, G. A., & Engdahl, C. (2019) · Bone · doi:10.1016/j.bone.2019.115149 · Cited by 22
Wu, Q. F., Xiao, X., & Xu, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020499 · Cited by 25
“5) the mean value for young, healthy women [7].”
BackgroundLewiecki, E. M., Binkley, N., Clark, P., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05541-7 · Cited by 22
Self-citationTang, L., An, S., Zhang, Z., Fan, X., Guo, J., Sun, L., & Ta, D. (2020) · Bone · doi:10.1016/j.bone.2020.115610 · Cited by 22
Real-world bone turnover marker use: impact on treatment decisions and fracture
Lane, N. E., Saag, K. G., O’Neill, T. J., Manion, M. A., Shah, R. A., Klause, U., & Eastell, R. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05734-0 · Cited by 22
“The International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine (IOF-IFCC) Bone Markers Working Group has identified CTX and PINP as promising markers for providing clinically useful information for monitoring osteoporosis treatment [7], and recommends that CTX and…”
BackgroundInfluentialEffendy, N. M., Abdullah, S., Yunoh, M. F. M., & Shuid, A. N. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0567-x · Cited by 28
Zhou, L., Song, J., Yang, S., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3930-6 · Cited by 22
Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience
Edwards, B. J.-A., Sun, M., Zhang, X., Holmes, H. M., Song, J., Khalil, P., Karuturi, M. S., Shah, J. B., Dinney, C. P., Gagel, R. F., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3962-7 · Cited by 27
Jung, J., Han, S. H., Hong, Y. S., Park, S., Ju, J. H., & Kang, K. Y. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1510877 · Cited by 24
Osteoporosis Imaging in the Geriatric Patient
Heilmeier, U., Youm, J., Torabi, S., & Link, T. M. (2016) · Current Radiology Reports · doi:10.1007/s40134-016-0144-1 · Cited by 21
Barker, A. L., Soh, S., Sanders, K. M., Pasco, J. A., Khosla, S., Ebeling, P. R., Ward, S. A., Peeters, G. M. E. E., Talevski, J., Cumming, R. G., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2018-026876 · Cited by 25
Cui, R., Sun, S., Zhong, N., Xu, M., Cai, H., Zhang, G., Qu, S., & Sheng, H. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05374-4 · Cited by 21
Wen, F., Du, H., Ding, L., Hu, J., Huang, Z., Huang, H., Li, K., Mo, Y., & Kuang, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234123 · Cited by 25
Uterine Metabolomic Analysis for the Regulation of Eggshell Calcification in Chickens
Wang, X., Zhu, P., Sun, Z., Zhang, J., & Sun, C. (2021) · Metabolites · doi:10.3390/metabo11090575 · Cited by 31
Stimulant use and bone health in US children and adolescents: analysis of the NHANES data
Fu, Y., Wang, G., Liu, J., Li, M., Dong, M., Zhang, C., Xu, R., & Liu, X. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-021-04356-w · Cited by 21
“Accumulating evidence indicates that bone metabolism is influenced by the use of chronic medication, such as glucocorticoids, anticonvulsants, and anticoagulants [4].”
BackgroundHolubiac, I. Ș., Leuciuc, F. V., Crăciun, M. D., & Dobrescu, T. (2022) · Sensors · doi:10.3390/s22051904 · Cited by 35
“According to the National Osteoporosis Foundation, the indications for DEXA investigation are: (a) women aged 65 and over and men aged 70 and over; (b) postmenopausal women and men ≥50 years of age with other risk factors involved; (c) postmenopausal women and men ≥50 years of age who have suffered a fracture at or af…”
MethodShi, L., Wu, J., Chen, B., Li, S., & Huang, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.844218 · Cited by 23
“Among osteoporotic fractures, the spine, hip, distal forearm, and proximal humerus fractures tend to be the most frequent (6, 7).”
BackgroundSacral Insufficiency Fractures
Rickert, M. M., Windmueller, R. A., Ortega, C. A., Devarasetty, V. V. N. M., Volkmar, A. J., Waddell, W. H., & Mitchell, P. M. (2022) · JBJS Reviews · doi:10.2106/jbjs.rvw.22.00005 · Cited by 26
Skornitzke, S., Vats, N., Kopytova, T., Tong, E. W. Y., Hofbauer, T., Weber, T. F., Rehnitz, C., von Stackelberg, O., Maier-Hein, K. H., Stiller, W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24546-2 · Cited by 24
Harahap, I. A., Kuligowski, M., SCHMIDT, M. T., Kolodziejski, P. A., & Suliburska, J. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3571 · Cited by 22
Preoperative Optimization for Orthopaedic Surgery: Steps to Reduce Complications
Shapiro, L. M., Bolognesi, M. P., Bozic, K. J., & Kamal, R. N. (2023) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-22-00192 · Cited by 25
Improving bone mineral density reporting to patients with an illustration of personal fracture risk
Edmonds, S. W., Cram, P. M., Lü, X., Roblin, D. W., Wright, N. C., Saag, K. G., & Solimeo, S. L. (2014) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-014-0101-y · Cited by 21
Lewiecki, E. M., & Binkley, N. (2009) · Endocrine Practice · doi:10.4158/ep09107.ra · Cited by 21
Self-citationSund, R., Honkanen, R., Johansson, H., Odén, A., McCloskey, E. V., Kanis, J. А., & Kröger, H. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9860-9 · Cited by 27
The Efficacy of Vitamin D Supplementation During a Prolonged Submarine Patrol
Gasier, H. G., Gaffney‐Stomberg, E., Young, C. R., McAdams, D. C., Lutz, L. J., & McClung, J. P. (2014) · Calcified Tissue International · doi:10.1007/s00223-014-9886-z · Cited by 24
Patient Perceptions of Osteoporosis Treatment Thresholds
Neuner, J. M., & Schapira, M. M. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130548 · Cited by 22
Fracture prediction from repeat BMD measurements in clinical practice
Leslie, W. D., Brennan-Olsen, S. L., Morin, S. N., & Lix, L. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3259-y · Cited by 23
Chodick, G., Moser, S. S., & Goldshtein, I. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2016.1171145 · Cited by 25
Ardıç, F. (2014) · Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi · doi:10.5152/tftrd.2014.33716 · Cited by 62
Inhaled glucocorticoids are associated with vertebral fractures in COPD patients
Gonçalves, P. A., Neves, R. S., Neto, L. V., Madeira, M., Guimarães, F. S., de Mendonça, L. M. C., Lopes, A. J., & Farias, M. L. F. (2017) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-017-0854-3 · Cited by 23
Rebello, D., Anjelly, D., Grand, D., Machan, J. T., Beland, M. D., Furman, M. S., Shapiro, J. M., LeLeiko, N. S., Sands, B. E., Mallette, M. M., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4444-6 · Cited by 21
Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis
Pieralice, S., Vigevano, F., Toro, R. D., Napoli, N., & Maddaloni, E. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1060-y · Cited by 23
Engelke, K., Stampa, B., Steiger, P., Fuerst, T. P., & Genant, H. K. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0577-2 · Cited by 21
Grossmann, M., Ramchand, S. K., Milat, F., Vincent, A. J., Lim, E., Kotowicz, M. A., Hicks, J., & Teede, H. J. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50280 · Cited by 21
Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss
Castelo‐Branco, C., Hidalgo, M. J. C., Palacios, S., Recasens, M. C., Fernández-Pareja, A., Carbonell-Abella, C., Manasanch, J., & Haya, J. (2019) · Climacteric · doi:10.1080/13697137.2019.1685488 · Cited by 21
Qiao, D., Liu, X., Tu, R., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2018-028593 · Cited by 21
Leslie, W. D., Schousboe, J. T., Morin, S. N., Martineau, P., Lix, L. M., Johansson, H., McCloskey, E. V., Harvey, N. C., & Kanis, J. А. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05313-3 · Cited by 24
Braungart, S., Craigie, R., Farrelly, P. J., & Losty, P. D. (2020) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2020.02.057 · Cited by 22
Naranjo, A., Ojeda, S., Giner, M., Balcells, M., Canals, L., Trujillo, J. M. C., Duaso, E., Mora-Fernández, J., Pablos‐Hernández, C., González, A., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-0693-z · Cited by 25
Northuis, C. A., Crandall, C. J., Margolis, K. L., Diem, S. J., Ensrud, K. E., & Lakshminarayan, K. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.104976 · Cited by 21
“The FRAX risk score was dichotomized to <3% as low/ medium risk and ≥3% as high risk for 10-year hip fracture risk, according to the National Osteoporosis Foundation treatment recommendations regarding treatment of osteopenia.(23)”
MethodYang, J., Cosman, F., Stone, P. W., Li, M., & Nieves, J. W. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05588-6 · Cited by 22
Self-citationAre Nursing Home Residents With Dementia Appropriately Treated for Fracture Prevention?
Niznik, J. D., Li, X., Gilliam, M., Hanson, L. C., Aspinall, S. L., Colon-Emeric, C. S., & Thorpe, C. T. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.11.019 · Cited by 21
Updates on Osteoporosis in Men
Diab, D. L., & Watts, N. B. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.001 · Cited by 26
Foessl, I., Bassett, J. H. D., Bjørnerem, Å., Busse, B., Calado, Â., Chavassieux, P., Christou, M., Douni, E. K., Fiedler, I. A. K., Fonseca, J. E., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720728 · Cited by 22
Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis
Benlidayı, İ. C., Başaran, S., EVLİCE, A. T., Erdem, M., & Demirkıran, M. (2015) · Acta Clinica Belgica · doi:10.1179/2295333715y.0000000002 · Cited by 23
Fujiyoshi, A., Polgreen, L. E., Hurley, D. L., Gross, M. D., Sidney, S., & Jacobs, D. R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2198 · Cited by 23
Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia
El‐Maouche, D., Hannah‐Shmouni, F., Mallappa, A., Hargreaves, C. J., Avila, N. A., & Merke, D. P. (2019) · Clinical Endocrinology · doi:10.1111/cen.13996 · Cited by 20
Bone health in patients with inflammatory bowel disease
Kreienbühl, A., Rogler, G., Burri, E., Biedermann, L., Meier, C., Juillerat, P., Restellini, S., Hruz, P. L., Vavricka, S. R., Aeberli, D., et al. (2024) · Swiss Medical Weekly · doi:10.57187/s.3407 · Cited by 24
Strategies for preventing bone loss in populations with insufficient calcium and vitamin D intake
Yeum, K., Ju, S.-Y., & Choe, U. (2025) · Nutrition Research and Practice · doi:10.4162/nrp.2025.19.2.155 · Cited by 28
“This increases the risk of hip and vertebral fractures, common in individuals with osteoporosis, which significantly contribute to morbidity, reduced quality of life, and higher mortality rates in these populations [23].”
van der Velde, N., Seppala, L. J., Herrero, Á. C., Annweiler, C., Jónsdóttir, A. B., Blain, H., Dionyssiotis, Y., Duque, S., Frith, J., Francis, B. N., et al. (2025) · European Geriatric Medicine · doi:10.1007/s41999-025-01206-y · Cited by 37
Jung, S. Y., Sohn, H. S., Park, E.-J., Suh, H. S., Park, J. W., & Kwon, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150531 · Cited by 20
Atsumi, Y., Rino, Y., Wada, H., Kitani, Y., Ozawa, Y., Aoyama, T., Oshima, T., Yukawa, N., Yoshikawa, T., & Masuda, M. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0835-9 · Cited by 20
Attard, C. C., Cameron‐Pimblett, A., Puri, D., Elliot, J., Wilson, J., Talaulikar, V. S., Davies, M. C., & Conway, G. S. (2019) · Clinical Endocrinology · doi:10.1111/cen.14110 · Cited by 20
Do patients that fracture with normal DXA-measured BMD have normal bone?
Bandaru, S., Hare, K. J., Krueger, D. C., & Binkley, N. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00745-0 · Cited by 22
Ten-year fracture risk predicted by proximal femur Hounsfield units
Christensen, D. L., Nappo, K. E., Wolfe, J. A., Tropf, J. G., Berge, M., Wheatley, B. M., Saxena, S., Yow, B. G., & Tintle, S. M. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05477-y · Cited by 21
Earp, B. E., Kallini, J. R., Collins, J. E., Benavent, K. A., Tintle, S. M., & Rozental, T. D. (2020) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001994 · Cited by 25
Metaanalysis Reveals Genetic Correlates of Osteoporosis Pathogenesis
Hasan, L. K., Aljabban, J., Rohr, M., Mukhtar, M., Adapa, N., Salim, R., Aljabban, N., Syed, S. A., Syed, S., Panahiazar, M., et al. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200951 · Cited by 21
Liu, Z., Zhang, M., Shen, Z., Ke, J., Zhang, D., & Yin, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243851 · Cited by 24
Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women
Izano, M. A., Lo, J. C.-M., Adams, A. L., Ettinger, B. B., Ott, S. M., Chandra, M., Hui, R. L., Niu, F., Li, B. H., & Neugebauer, R. S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25190 · Cited by 27
Xu, X., Zhang, M., Fei, Z., Sheng, H., Qu, S., & Cui, R. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05775-5 · Cited by 20
Anderson, P. A., Freedman, B. A., Brox, W. T., & Shaffer, W. O. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.01248 · Cited by 25
Lüthje, P. M. J., Nurmi-Lüthje, I., Tavast, N., Villikka, A., & Kataja, M. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01826-x · Cited by 19
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.